By its Decision no 865/2024, adopted on the 15th of November 2024, the Hellenic Competition Commission (HCC), in Chamber, unanimously approved, pursuant to Article 8 (3) of Greek Law 3959/2011, the notified concentration concerning the acquisition by acquisition by IMITHEA SA of sole control over certain assets of EUROMEDICA SA and its parent companies

IMITHEA, controlled by the STRIX/BLANTYRE Group, is based in Athens and offers hospital services via the “Henry Dunant” hospital.  Τhe Target business comprises of several private clinics, rehabilitation centers and other holdings that are jointly controlled by STRIX/BLANTYRE and FARALLON Groups, as well as EUROMEDICA Rhodes, which is controlled solely by the FARALLON Group.

The concentration, horizontal in nature, primarily leads to a qualitative change of control (since STRIX/BLANTYRE group already has joint control over all but one of the assets that constitute the Target Business). Moreover, no affected by the concentration relevant market was identified, as the statutory criterion (combined market share of at least 15% ) was not met.

The HCC, by its decision, concluded that the concentration is not expected to affect the competitive conditions in any of the relevant markets concerned. Therefore, whereas the concentration falls within the scope of article 6(1) of Greek Law 3959/2011, the HCC, by its decision, concluded that it does not raise serious concerns as to its compatibility with competition rules in the relevant markets it concerns.